Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles Divita III exercised equity awards and sold shares. On September 10, 2026, performance stock units for 3,642 shares and restricted stock units for 39,160 shares converted on a one-for-one basis into common stock. On September 11, 2026, he sold 17,805 common shares at $6.104 per share, with the filing stating the sale was to cover tax withholding obligations related to these vestings.
Teladoc Health, Inc. (TDOC) is the issuer for which Charles Divita III filed a notice of proposed sale of common stock under Rule 144. The notice covers a planned sale of 17,805 shares of Teladoc common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $108,683.50.
The shares relate to restricted stock vesting on September 10, 2026, and the filer notes that the sale includes an amount necessary to cover a tax obligation arising from the settlement of a vested equity award distribution. In the prior three months, Charles Divita reported additional Teladoc common stock sales totaling 36,401 shares for aggregate proceeds of $240,944.59.
Teladoc Health, Inc. (TDOC) reported that Carlos Nueno, President, International, had restricted stock units convert into a total of 13,273 shares of common stock on September 1, 2026, on a one-for-one basis. On September 2, 2026, he sold 6,200 shares at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the RSU vesting. No Rule 10b5-1 trading plan is reported.
Teladoc Health, Inc. (TDOC) reported insider equity activity by Chief Legal Officer and Secretary Adam C. Vandervoort. On September 1, 2026, his restricted stock units and performance stock units were converted into an aggregate of 14,928 shares of common stock on a one-for-one basis as vesting occurred. On September 2, 2026, he sold 7,573 shares of common stock at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the vesting of these awards. No Rule 10b5-1 trading plan is reported.
Teladoc Health, Inc. (TDOC) officer Kelly Bliss, President, U.S. Group Health, reported vesting and settlement of equity awards and a related sale. On September 1, 2026, she converted 15,311 restricted and performance stock units into the same number of Teladoc common shares. On September 2, 2026, she sold 7,357 common shares at $6.301 per share, with the company stating the sale was to cover tax withholding obligations arising from the vesting of her stock unit awards. Following these transactions, she continues to hold 7,798 performance stock units directly.
Teladoc Health, Inc. (TDOC) reports that Chief Accounting Officer Joseph Ronald Catapano settled equity awards and a related tax sale. On September 1, 2026, he converted 833 restricted stock units and 39 performance stock units into the same number of TDOC common shares on a one-for-one basis. On September 2, 2026, he sold 274 common shares at $6.301 per share, with the company stating this sale was to cover the tax withholding obligation arising from the vesting of these awards. Following the September 1 transactions, 5,001 restricted stock units and 232 performance stock units remained outstanding. No Rule 10b5-1 trading plan is indicated.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles DiVita III had restricted and performance stock units vest into common stock and sold a portion of shares. On September 1, 2026, 42,277 restricted stock units and 1,966 performance stock units converted one-for-one into common shares. On September 2, 2026, 18,327 common shares were sold at $6.30 per share to cover tax withholding obligations related to these vestings. No Rule 10b5-1 trading plan is reported for these transactions.
Teladoc Health, Inc. (TDOC) reports that Fernando M. Rodrigues, President of BetterHelp, converted a total of 15,251 restricted stock units into an equal number of common shares on September 1, 2026, then sold 15,251 common shares on September 2–3, 2026. One sale covered tax withholding on RSU vesting and another was executed under a Rule 10b5-1 trading plan adopted on November 3, 2025.
Teladoc Health, Inc. (TDOC) is the issuer for a planned sale of common stock reported under Rule 144 by officer Fernando Madeira Rodrigues. The notice covers up to 9,812 shares of common stock, to be sold through Fidelity Brokerage Services LLC.
The filing also lists prior sales of Teladoc common stock by Fernando Madeira Rodrigues during the past three months, including transactions on June 3, 2026 and September 2, 2026, with total reported proceeds in the tens of thousands of dollars.
Teladoc Health, Inc. (TDOC) discloses a planned sale of its common stock under Rule 144 by officer Kelly M. Bliss. A total of 7,357 shares are planned to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $46,358.67 as of September 2, 2026.
The shares were acquired on September 1, 2026 through restricted stock vesting as compensation, and the sale includes shares needed to cover a tax obligation arising from settlement of a vested equity award distribution. The notice also lists several prior sales of Teladoc common stock by Kelly M. Bliss during the preceding three months.